Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
Your insights matter. From J D Faccinetti – co-founder and chief editor – In the awareness business coming up with new, fresh, creative ideas is essential to get your message across, particularly these days when breaking
Dr. Alan Krasner, Chief Medical Officer, and Dr. Chris Cook, Medical Director, Endocrinology at Crinetics Pharmaceuticals offer an in-depth look at clinical studies. In this podcast, we cover a promising molecule – CRNOO808 – under
A few weeks ago, Dan Jeffreys, a UK based author, musician, and patient advocate sent me a message to tell me about his latest project. He told me he started AcroTales to encourage people to share their
As we reported a few months back, the Canadian International Acromegaly conference offered exciting presentations and discussions. If you have acromegaly, have a family member that suffers from the disease, or you are a healthcare
The third podcast in our series on drug development touches on the effort that industry is making to partner with patients to understand needs, preferences, and attitudes, and to develop insights that would result in
This is the first in a series of 6 podcasts on the ins and outs of drug development. In it, we discuss the journey that a promising molecule takes to develop into a life-saving medication and
We are thrilled to announce that Acromegaly will be the focus of a PFDD (Patient-Focused Drug Development) meeting sponsored by Acromegaly Community Inc., a patient support organization based in the US. The meeting will take
From the desk of Jorge D Faccinetti, co-founder – The Spanish Society of Endocrinology or SEEN (Sociedad Española de Endocrinologia y Nutricion) had their annual conference – Congreso, in Spanish – this past October in Bilbao,
From Jorge D Faccinetti, co-founder – Take the bull by the horns. This is an expression that most likely originated in the American West, where it was a common but dangerous practice to wrestle with
The perception that scientists and healthcare professionals do not understand what patients go through when dealing with disease, particularly chronic disease, was the focus of a refreshing exercise this past month at Crinetics Pharmaceuticals. To
From the desk of Jorge D Faccinetti, cofounder – One word describes this conference: FUN! The National and International Canadian conference this past September in Toronto, Canada, was not only a good time, but it was
Don’t miss today’s podcasts. Sometimes it is through these genuine, unscripted chats that we get insight into what it is like to deal with chronic pituitary disease, in this case, acromegaly. This podcast is no